AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Hutchmed (China) Limited

Net Asset Value Apr 8, 2015

10503_dirs_2015-04-08_2dbf95e0-1e76-4aed-bc5a-48138cd7426c.html

Net Asset Value

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5867J

Hutchison China Meditech Limited

08 April 2015

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

Directors' Shareholding

London: Wednesday, 8 April 2015: Chi-Med received notifications on 8 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:-

Director Date of purchase Number of Shares purchased Purchase price Beneficial interest in Shares following purchases
Number of Shares % of total issued share capital
Simon To (Executive Director and Chairman) 2 April 2015

7 April 2015
10,000

48,000
GBP13.85

GBP13.85
127,000 0.24%
Edith Shih (Non-executive Director and Company Secretary) 2 April 2015

7 April 2015
10,000

2,000
GBP13.85

GBP13.85
60,000 0.11%

Ends

Enquiries

Chi-Med

   Christian Hogg, CEO
Telephone:        +852 2121 8200
Panmure Gordon (UK) Limited

   Richard Gray

   Andrew Potts
Telephone:        +44 20 7886 2500
Citigate Dewe Rogerson

   Anthony Carlisle

   David Dible
Telephone:       +44 20 7638 9571

Mobile:             +44 7973 611 888

Mobile:             +44 7967 566 919

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: www.chi-med.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSSSWSWAFISEFL

Talk to a Data Expert

Have a question? We'll get back to you promptly.